NAUT Nautilus Biotechnology Inc

Price (delayed)

$2.68

Market cap

$340.57M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.46

Enterprise value

$354.82M

?
Relative Growth: Rel. Growth: 8
Relative Strength: Rel. Strength: 94
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 13

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics ...

Highlights
Nautilus Biotechnology's net income has increased by 17% YoY and by 3.2% QoQ
NAUT's EPS is up by 15% year-on-year and by 2.1% since the previous quarter
The quick ratio has contracted by 32% YoY and by 12% from the previous quarter
The equity has decreased by 26% YoY and by 8% from the previous quarter

Key stats

What are the main financial stats of NAUT

NAUT stock price

How has the Nautilus Biotechnology stock price performed over time
Intraday
3.88%
1 week
3.08%
1 month
-7.27%
1 year
245.85%
YTD
37.44%
QTD
-30.93%

Financial performance

How have Nautilus Biotechnology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$64.12M
Net income
-$57.09M
Gross margin
N/A
Net margin
N/A
Nautilus Biotechnology's operating income has increased by 19% YoY and by 4.1% from the previous quarter
Nautilus Biotechnology's net income has increased by 17% YoY and by 3.2% QoQ

Price vs fundamentals

How does NAUT's price correlate with its fundamentals

Growth

What is Nautilus Biotechnology's growth rate over time

Valuation

What is Nautilus Biotechnology stock price valuation
P/E
N/A
P/B
2.35
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
NAUT's EPS is up by 15% year-on-year and by 2.1% since the previous quarter
The stock's price to book (P/B) is 61% more than its 5-year quarterly average of 1.4 and 51% more than its last 4 quarters average of 1.5
The equity has decreased by 26% YoY and by 8% from the previous quarter

Efficiency

How efficient is Nautilus Biotechnology business performance
The return on equity has declined by 10% year-on-year and by 4.2% since the previous quarter
The ROIC is down by 7% year-on-year
NAUT's return on assets is down by 7% year-on-year and by 3.2% since the previous quarter

Dividends

What is NAUT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NAUT.

Financial health

How did Nautilus Biotechnology financials performed over time
The current ratio fell by 32% YoY and by 11% QoQ
The quick ratio has contracted by 32% YoY and by 12% from the previous quarter
Nautilus Biotechnology's debt is 80% lower than its equity
Nautilus Biotechnology's debt to equity has increased by 33% YoY and by 5% from the previous quarter
The equity has decreased by 26% YoY and by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.